Advertisement
A vs HBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Buy and HBIO is a Hold.
Aroon Indicator for A shows an upward move is likely
A's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 144 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on A as a result. In 58 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 17 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 68 cases where A's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 28 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.692) is normal, around the industry mean (67.298). P/E Ratio (34.334) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
HBIO in -2.90% downward trend, declining for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HBIO declined for three days, in 285 of 331 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HBIO moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 8 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 46 cases where HBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
HBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on HBIO as a result. In 80 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for HBIO just turned positive on November 09, 2026. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.
Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in 159 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 82 of 108 cases where HBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.130) is normal, around the industry mean (4.964). P/E Ratio (-3.635) is within average values for comparable stocks, (40.591). HBIO's Projected Growth (PEG Ratio) (14.400) is slightly higher than the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
A | HBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 87 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 60 | 100 | |
SMR RATING 1..100 | 45 | 98 | |
PRICE GROWTH RATING 1..100 | 16 | 38 | |
P/E GROWTH RATING 1..100 | 45 | 84 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (24) in the Biotechnology industry is significantly better than the same rating for HBIO (97). This means that A’s stock grew significantly faster than HBIO’s over the last 12 months.
A's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for HBIO (100). This means that A’s stock grew somewhat faster than HBIO’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for HBIO (98). This means that A’s stock grew somewhat faster than HBIO’s over the last 12 months.
A's Price Growth Rating (16) in the Biotechnology industry is in the same range as HBIO (38). This means that A’s stock grew similarly to HBIO’s over the last 12 months.
A's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for HBIO (84). This means that A’s stock grew somewhat faster than HBIO’s over the last 12 months.
| A | HBIO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | 1 day ago 47% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 78% |
| Advances ODDS (%) | 1 day ago 62% | 11 days ago 72% |
| Declines ODDS (%) | 8 days ago 63% | 4 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while HBIO’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- HBIO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while HBIO’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- HBIO’s TA Score: 4 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +4.76% price change this week, while HBIO (@Pharmaceuticals: Other) price change was +5.70% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.11%. For the same industry, the average monthly price growth was -5.15%, and the average quarterly price growth was +40.44%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was +4.73%, and the average quarterly price growth was +18.71%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
HBIO is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical Specialties (-1.11% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+5.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
HBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.
| Ticker / NAME | Correlation To HBIO | 1D Price Change % | ||
|---|---|---|---|---|
| HBIO | 100% | +8.73% | ||
| IRMD - HBIO | 46% Loosely correlated | +0.73% | ||
| A - HBIO | 37% Loosely correlated | +3.10% | ||
| RVTY - HBIO | 36% Loosely correlated | +3.62% | ||
| MTD - HBIO | 35% Loosely correlated | +2.33% | ||
| NEOG - HBIO | 34% Loosely correlated | +2.72% | ||
More | ||||